glp 1 black box warning TGA issues over GLP-1-based drugs' potential to cause rare eye disorder The FDA sent a warning

Its introduction should be guided by a thorough assessment of patient history, lifestyle factors, and clinical goals, alongside structured monitoring to ensure safety and efficacy

Manufactured in a cGMP registered facility with high manufacturing and sourcing standards

Calycosin inhibited autophagy and oxidative stress in chronic kidney disease skeletal muscle atrophy by regulating AMPK/SKP2/CARM1 signalling pathway

Extended-release exenatide (Bydureon BCise) has an apparent terminal half-life of approximately 2 weeks due to its depot formulation, with drug concentrations potentially persisting for 8-10 weeks after discontinuation